Middle East Research Journal of Nursing
ISSN 2789-8679 (Print) & ISSN: 2958-2016 (Online)
Frequency: Bi-Monthly
DOI: https://doi.org/10.36348/merjn.2024.v04i05.004

KUWAIT SCHOLARS PUBLISHER
Website: http://www.kspublisher.com/
Email: office@kspublisher.com

Strategies for Coping with Hemolysis in Pregnancy for Sickle Cell Anemia: A Review

Emmanuel Ifeanyi Obeagu[1*], Getrude Uzoma Obeagu[2]
[1]Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda
[2]School of Nursing Science, Kampala International University, Ishaka, Uganda

Abstract: Sickle cell anemia (SCA) is a genetic disorder that poses significant challenges during pregnancy, primarily due to increased hemolysis caused by the physiological demands of pregnancy. Hemolysis, the destruction of red blood cells, exacerbates anemia and can lead to severe maternal and fetal complications, including preterm birth, growth restriction, and increased maternal morbidity. Effective strategies for coping with hemolysis during pregnancy in SCA are crucial for improving outcomes for both mother and baby. This review highlights key strategies for managing hemolysis in pregnant women with SCA, including transfusion therapy, pharmacological interventions, and nutritional support. Transfusion therapy, especially exchange transfusions, can effectively reduce the proportion of sickled red cells, improving oxygen delivery and minimizing hemolysis. Pharmacological interventions like hydroxyurea, traditionally avoided in pregnancy, are being reconsidered for their potential benefits, while antioxidant therapy and folic acid supplementation are crucial in reducing oxidative stress and supporting red blood cell production.

Keywords: Sickle Cell Anemia, Pregnancy, Hemolysis, Transfusion Therapy, Hydroxyurea.

Review Paper

***Corresponding Author:**
Emmanuel Ifeanyi Obeagu
Department of Medical Laboratory Science, Kampala International University, Uganda

How to cite this paper:
Emmanuel Ifeanyi Obeagu & Getrude Uzoma Obeagu (2024). Strategies for Coping with Hemolysis in Pregnancy for Sickle Cell Anemia: A Review. *Middle East Res J Nursing, 4*(5): 76-79.

Article History:
| Submit: 26.09.2024 |
| Accepted: 25.10.2024 |
| Published: 26.10.2024 |

INTRODUCTION

Sickle cell anemia (SCA) is a hereditary blood disorder that results from a mutation in the β-globin gene, leading to the production of abnormal hemoglobin S (HbS). The hallmark of SCA is the sickling of red blood cells (RBCs), which can cause chronic hemolysis, vaso-occlusive crises (VOCs), and multi-organ complications. Hemolysis, or the breakdown of RBCs, is particularly problematic in pregnant women with SCA due to the increased physiological demands of pregnancy. Hemolysis leads to anemia, exacerbates sickling, and significantly increases the risk of pregnancy complications, including preeclampsia, intrauterine growth restriction, and preterm delivery [1-4]. Pregnancy induces physiological changes that challenge the body's ability to manage hemolysis [5]. Blood volume increases by approximately 50%, oxygen demands rise, and there is an increased need for adequate red cell production to support both maternal and fetal needs. In women with SCA, this additional burden often accelerates hemolysis, leading to worsened anemia and other complications [6]. Left unmanaged, the consequences of hemolysis in pregnancy can be severe, leading to maternal morbidity, poor fetal outcomes, and even maternal mortality [7]. As such, effective strategies to cope with hemolysis in pregnant women with SCA are paramount.

The management of hemolysis in pregnancy for women with SCA requires a multi-pronged approach [8]. Traditional methods include blood transfusions, which help improve oxygen delivery by increasing hemoglobin levels and reducing the proportion of sickled cells. While transfusions are often necessary, they come with risks such as iron overload and alloimmunization, which need to be carefully monitored. Advances in pharmacological management have introduced drugs like hydroxyurea, which increases fetal hemoglobin (HbF) and reduces sickling; however, its use during pregnancy has been controversial due to potential teratogenic effects, prompting further investigation. Nutritional interventions are also critical in managing hemolysis in pregnancy [9]. Folic acid supplementation, for instance, is vital for supporting increased red blood cell production and preventing folate deficiency anemia. Antioxidant therapy is emerging as a promising strategy for reducing oxidative stress, which is exacerbated by chronic hemolysis and contributes to further red cell destruction. Hydration, another key component, helps reduce the risk of sickling and VOCs by maintaining optimal blood

viscosity, while oxygen therapy may be necessary in severe cases of hypoxia during pregnancy or delivery.

Pathophysiology of Hemolysis in Sickle Cell Anemia

Sickle cell anemia (SCA) is a genetic disorder caused by a point mutation in the β-globin gene, which leads to the production of abnormal hemoglobin known as hemoglobin S (HbS). Under normal oxygenation conditions, HbS behaves like regular hemoglobin; however, when oxygen levels decrease, HbS polymerizes, causing red blood cells (RBCs) to assume a rigid, sickle shape. These sickled RBCs are less flexible, more fragile, and prone to premature destruction, a process known as hemolysis. Hemolysis in SCA can be both intravascular (within the bloodstream) and extravascular (primarily in the spleen and liver), leading to a variety of clinical complications [10-13]. Intravascular hemolysis occurs when sickled RBCs rupture directly within the bloodstream, releasing free hemoglobin and other cellular contents into the plasma [14]. The free hemoglobin released during hemolysis can bind to nitric oxide (NO), a potent vasodilator, reducing its availability in the circulation. This depletion of NO leads to vasoconstriction, contributing to complications such as hypertension and vascular damage. Free hemoglobin can also induce oxidative stress by producing reactive oxygen species (ROS), which further damage RBC membranes and exacerbate hemolysis. Additionally, the breakdown of heme, a component of hemoglobin, releases toxic substances like free iron, further promoting oxidative stress and inflammation.

Extravascular hemolysis, on the other hand, occurs when sickled RBCs are recognized as abnormal by the reticuloendothelial system (particularly in the spleen and liver) and are removed from circulation [15]. The rigid, deformed RBCs cannot pass easily through the small capillaries of these organs, leading to their destruction by macrophages. While extravascular hemolysis is less damaging in terms of oxidative stress, it contributes to chronic anemia in SCA patients, as the body struggles to replace the destroyed RBCs quickly enough to meet the increased demand for oxygen transport. This chronic hemolytic state results in elevated levels of bilirubin, leading to jaundice, gallstones, and other related complications. The constant cycle of RBC sickling and hemolysis leads to a state of chronic anemia, which worsens during pregnancy due to the additional demand for oxygen and blood volume expansion [16]. During pregnancy, women with SCA are at increased risk for hemolytic crises, where the rate of RBC destruction overwhelms the body's compensatory mechanisms [17]. These hemolytic crises not only exacerbate anemia but also increase the risk of vaso-occlusive crises (VOCs), which occur when sickled cells obstruct blood flow in small vessels, leading to tissue ischemia and pain. Hemolysis in SCA also triggers a cascade of inflammatory responses. The release of cell-free hemoglobin, heme, and iron from lysed RBCs activates the immune system, promoting the release of pro-inflammatory cytokines and chemokines. These inflammatory mediators further damage the vascular endothelium, enhancing the adherence of sickled RBCs to blood vessel walls, thereby perpetuating VOCs and increasing the risk of complications such as acute chest syndrome, stroke, and organ damage.

Strategies for Coping with Hemolysis in Pregnancy

Managing hemolysis during pregnancy in women with sickle cell anemia (SCA) presents unique challenges that require a multidisciplinary approach. Hemolysis, the premature destruction of red blood cells (RBCs), is a central feature of SCA that worsens during pregnancy due to increased metabolic demands and blood volume expansion. To mitigate the harmful effects of hemolysis, a combination of strategies—including transfusion therapy, pharmacological interventions, nutritional support, and emerging treatments—can be employed to optimize maternal and fetal outcomes.

1. Blood Transfusion Therapy

Blood transfusion is one of the most effective strategies for coping with hemolysis in pregnant women with SCA [18]. Regular transfusions help increase hemoglobin levels, reduce the proportion of sickled RBCs, and improve oxygen-carrying capacity, thereby alleviating anemia. Transfusion can be performed as simple transfusion or exchange transfusion. Exchange transfusion, in particular, is beneficial because it not only replenishes the patient's RBCs but also removes sickled cells, reducing the risk of vaso-occlusive crises (VOCs) and other complications associated with SCA during pregnancy. However, transfusion therapy comes with risks, including iron overload, alloimmunization, and transfusion reactions. Careful monitoring of iron levels and the use of iron chelation therapy in cases of iron overload are essential components of managing these risks.

2. Pharmacological Interventions

Pharmacological management of hemolysis in pregnant women with SCA has evolved in recent years [19]. While some drugs like hydroxyurea are typically avoided during pregnancy due to potential teratogenic effects, they are being reconsidered for select patients due to their ability to increase fetal hemoglobin (HbF) levels and reduce sickling. Hydroxyurea, which stimulates the production of HbF, can decrease hemolysis by diluting the concentration of hemoglobin S (HbS) in RBCs. Though more studies are needed to fully establish its safety during pregnancy, some data suggest it may benefit women at high risk of complications. Additionally, low-dose aspirin and anticoagulants may be used to prevent thromboembolic events, which are more common in pregnant women with SCA. Antioxidants, such as L-glutamine, have also been explored for their potential to reduce oxidative stress and RBC damage during hemolysis.

3. Nutritional Support

Nutritional support plays a critical role in managing hemolysis and anemia in pregnancy [20]. Pregnant women with SCA require higher levels of folic acid due to the increased turnover of RBCs [21]. Folic acid supplementation is essential to support erythropoiesis and prevent folate deficiency anemia. Additionally, ensuring adequate hydration is vital to prevent dehydration, which can exacerbate sickling and lead to VOCs. Proper hydration helps maintain optimal blood viscosity and reduce the risk of RBC clumping and vascular occlusion. A balanced diet rich in antioxidants (e.g., vitamins C and E) can help reduce oxidative stress, which is elevated in SCA due to chronic hemolysis. Zinc supplementation has also been shown to promote RBC production and reduce the incidence of hemolytic crises in some patients.

4. Oxygen Therapy and Pain Management

Hypoxia is a significant risk during pregnancy, as the oxygen demands of both the mother and fetus increase [22]. Oxygen therapy may be employed during acute sickle cell crises or in cases of severe anemia to ensure adequate oxygenation and prevent maternal and fetal complications. Pain management is another critical component of care, especially during VOCs. While non-steroidal anti-inflammatory drugs (NSAIDs) are generally avoided in pregnancy, opioids and other analgesics may be used under close supervision to manage severe pain. However, careful consideration is necessary to avoid potential risks to the fetus and to prevent opioid dependence.

5. Emerging Therapies

New therapies are being developed to address the underlying causes of hemolysis in SCA. Gene therapy, including techniques such as CRISPR-Cas9, is a promising area of research that aims to correct the genetic mutation responsible for sickle cell disease [23]. While gene therapy is still in experimental stages and not yet widely available, it has the potential to offer a curative solution by targeting the root cause of hemolysis. Another emerging therapy, L-glutamine, has been approved for use in SCA patients and works by reducing oxidative stress and preventing RBC sickling. Although its use during pregnancy has not been fully studied, it represents a potential therapeutic option for managing hemolysis in the future. Additionally, therapies that target adhesion molecules on sickled RBCs and the endothelium, such as P-selectin inhibitors, could reduce VOCs and hemolysis by decreasing RBC adhesion and vascular obstruction.

6. Comprehensive Prenatal Care and Monitoring

A multidisciplinary approach involving obstetricians, hematologists, and other specialists is essential for managing pregnant women with SCA. Frequent prenatal visits, close monitoring of hemoglobin levels, and regular screening for maternal and fetal complications are necessary to ensure optimal outcomes. Fetal growth and development must be closely monitored through ultrasound, as hemolysis and anemia can impair placental function and lead to intrauterine growth restriction. Additionally, early delivery may be considered in cases of severe maternal or fetal distress, with the timing of delivery based on the balance of risks to both mother and baby.

CONCLUSION

Coping with hemolysis during pregnancy in women with sickle cell anemia (SCA) requires a comprehensive and multifaceted approach to mitigate the risks posed to both maternal and fetal health. Hemolysis, a key feature of SCA, exacerbates the already increased physiological demands of pregnancy, contributing to anemia, vaso-occlusive crises (VOCs), and other complications that endanger the mother and the developing fetus. To address these challenges, a range of strategies must be employed, including blood transfusion therapy, pharmacological interventions, nutritional support, oxygen therapy, and emerging therapeutic options.

Blood transfusions remain a cornerstone of treatment, helping to manage anemia and reduce sickled red blood cells, while pharmacological advancements offer potential benefits despite their cautious use in pregnancy. Nutritional support, particularly through folic acid supplementation and antioxidants, plays a critical role in supporting red blood cell production and reducing oxidative stress. Oxygen therapy and effective pain management are necessary to address the complications of VOCs and hypoxia that often arise during pregnancy in women with SCA. Furthermore, emerging therapies, such as gene editing and new pharmacological agents, hold promise for future advancements in treating hemolysis.

REFERENCES

1. Obeagu, E. I., Ochei, K. C., Nwachukwu, B. N., & Nchuma, B. O. (2015). Sickle cell anaemia: a review. *Scholars Journal of Applied Medical Sciences*, *3*(6B), 2244-52.
2. Obeagu, E. I. (2020). Erythropoeitin in sickle cell anaemia: a review. *International Journal of Research Studies in Medical and Health Sciences*, *5*(2), 22-8.
3. Agreen, F. C., & Obeagu, E. I. 2023). Anaemia among pregnant women: A review of African pregnant teenagers. *Journal of Public Health and Nutrition*, *6*(1), 138.
4. Obeagu, E. I., Obeagu, G. U., Chukwueze, C. M., Ikpenwa, J. N., & Ramos, G. F. (2022). Evaluation of protein C, protein S and fibrinogen of pregnant women with malaria in Owerri metropolis.

Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035, *2*(2), 1-9.
5. Obeagu, E. I., Obeagu, G. U., Hauwa, B. A. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. Journal home page: http://www. journalijiar. com.12(01).
6. Helvaci, M. R., Yilmaz, H., Yalcin, A., Muftuoglu, O. E., Abyad, A., & Pocock, L. (2021). Sickle cell anemia versus sickle cell diseases in adults. *Middle East Journal of Internal Medicine*, *14*(2).
7. van't Oever, R. M., Zwiers, C., de Winter, D., de Haas, M., Oepkes, D., Lopriore, E., & Verweij, E. J. (2022). Identification and management of fetal anemia due to hemolytic disease. *Expert Review of Hematology*, *15*(11), 987-998.
8. Feinberg, A. N., Shwayder, T. A., Tareen, R. S., & Tempark, T. (2013). Perspectives on management of pediatric dermatologic disorders. *Pediatric Psychodermatology: A Clinical Manual of Child and Adolescent Psychoneurocutaneous Disorders*, 3-68.
9. Muñoz, M., Peña-Rosas, J. P., Robinson, S., Milman, N., Holzgreve, W., Breymann, C., ... & Hardy, J. F. (2018). Patient blood management in obstetrics: management of anaemia and haematinic deficiencies in pregnancy and in the post-partum period: NATA consensus statement. *Transfusion medicine*, *28*(1), 22-39.
10. Obeagu, E. I., & Obeagu, G. U. (2024). Implications of climatic change on sickle cell anemia: A review. *Medicine*, *103*(6), e37127.
11. Obeagu, E. I. (2023). Depression in sickle cell anemia: an overlooked battle. *Int. J. Curr. Res. Chem. Pharm. Sci*, *10*(10), 41-4.
12. Obeagu, E. I., Ubosi, N. I., Obeagu, G. U., Egba, S. I., & Bluth, M. H. (2024). Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. *Medicine*, *103*(2), e36898.
13. Obeagu, E. I., & Obeagu, G. U. (2024). Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. *Elite Journal of Haematology*, *2*(3), 58-66.
14. Michel, J. B., & Martin-Ventura, J. L. (2020). Red blood cells and hemoglobin in human atherosclerosis and related arterial diseases. *International Journal of Molecular Sciences*, *21*(18), 6756.
15. Frimat, M., Boudhabhay, I., & Roumenina, L. T. (2019). Hemolysis derived products toxicity and endothelium: model of the second hit. *Toxins*, *11*(11), 660.
16. Doshi, H. U. (2021). Anemia in Pregnancy. *Clinical Cases in Obstetrics & Gynecology*, 1.
17. Enosolease, M. E. (2021). Haematological Disorders in Pregnancy. *Contemporary Obstetrics and Gynecology for Developing Countries*, 363-373.
18. Obeagu, E. I., Adias, T. C., & Obeagu, G. U. (2024). Advancing life: innovative approaches to enhance survival in sickle cell anemia patients. *Annals of Medicine and Surgery*, *86*(10), 6021-6036.
19. Ganesh, B., Rajakumar, T., Acharya, S. K., & Kaur, H. (2022). Sickle cell anemia/sickle cell disease and pregnancy outcomes among ethnic tribes in India: an integrative mini-review. *The Journal of Maternal-Fetal & Neonatal Medicine*, *35*(25), 4897-4904.
20. Goonewardene, M., Shehata, M., & Hamad, A. (2012). Anaemia in pregnancy. *Best practice & research Clinical obstetrics & gynaecology*, *26*(1), 3-24.
21. Galadanci, A. A., Abdulqadir, I., Gwarzo, A. K., & Gume, S. A. (2019). Relationship between Folate Status and Complete Blood Count (CBC) Parameters in Sickle Cell Anaemia (SCA) at Steady State in Aminu Kano Teaching Hospital, Kano, Nigeria. *International Journal of Research and Reports in Hematology*, *2*(1), 74-79.
22. Obeagu, E. I., & Obeagu, G. U. (2024). Hypoxia in Pregnancy: Implications for Fetal Development. *Int. J. Curr. Res. Chem. Pharm. Sci*, *11*(7), 39-50.
23. Demirci, S., Leonard, A., Haro-Mora, J. J., Uchida, N., & Tisdale, J. F. (2019). CRISPR/Cas9 for sickle cell disease: applications, future possibilities, and challenges. *Cell Biology and Translational Medicine, Volume 5: Stem Cells: Translational Science to Therapy*, 37-52.
24. Asare, E. V., Olayemi, E., Boafor, T., Dei-Adomakoh, Y., Mensah, E., Ghansah, H., ... & Oppong, S. A. (2017). Implementation of multidisciplinary care reduces maternal mortality in women with sickle cell disease living in low-resource setting. *American journal of hematology*, *92*(9), 872-878.